跳至主要内容
临床试验/NCT01569113
NCT01569113已完成4 期

A Prospective, Randomized, Double-blind Parallel-arm, Placebo-controlled Study to Assess the Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® (Ulipristal Acetate 30 mg) or Placebo.

HRA Pharma3 个研究点 分布在 3 个国家目标入组 76 人开始时间: 2012年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
76
试验地点
3
主要终点
Proportion of subjects with a Hoogland score consistent with ovarian quiescence (≤3) after 1 to 21 days of intake of COCP in both groups (preceded by the intake of ellaOne® or placebo).

研究概览

简要总结

The purposes of this study are to compare the effects on ovarian activity of quick starting a Combined Oral Contraceptive Pill (COCP) after ellaOne® or placebo intake.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Healthy women aged 18-35 years old
  • BMI < 30 Kg/m2
  • Not at risk of pregnancy
  • No use of progesterone-only-pill for 3 months before start of treatment cycle
  • No use of implant hormonal contraception for 3 months before start of treatment cycle
  • No use of levonorgestrel intrauterine system for 3 months before start of treatment cycle
  • No use of depo provera for 12 months before start of treatment cycle
  • Able to give informed consent.

排除标准

  • 未提供

研究组 & 干预措施

placebo + microgynon 30

Placebo Comparator

干预措施: placebo + ethinylestradiol/levonorgestrel (Drug)

ellaOne + microgynon 30

Experimental

干预措施: Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon) (Drug)

结局指标

主要结局

Proportion of subjects with a Hoogland score consistent with ovarian quiescence (≤3) after 1 to 21 days of intake of COCP in both groups (preceded by the intake of ellaOne® or placebo).

时间窗: Day 1 to day 21 of intake of microgynon 30

次要结局

  • Number of days of intake of COCP required to reach ovarian quiescence (Hoogland score ≤3) after the intake of ellaOne® or placebo.(Day 1 to day 21 of intake of microgynon 30)

研究者

发起方
HRA Pharma
申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验